

# Ola Landgren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10853251/publications.pdf>

Version: 2024-02-01

218  
papers

19,861  
citations

14655

66  
h-index

11607

135  
g-index

220  
all docs

220  
docs citations

220  
times ranked

15061  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. <i>Seminars in Oncology</i> , 2022, , .	2.2	1
2	Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>Blood Cancer Journal</i> , 2022, 12, 51.	6.2	2
3	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2160-2166.	7.0	2
4	Modern Myeloma Therapy + Sustained Minimal Residual Disease = (Functional) Cure!. <i>Journal of Clinical Oncology</i> , 2022, 40, 2863-2866.	1.6	5
5	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2760-2761.	1.3	1
6	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 15-23.	7.0	20
7	Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. <i>JAMA Oncology</i> , 2021, 7, 132.	7.1	21
8	A phase 1b study of once-a-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 226-233.	4.1	5
9	Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. <i>Environmental Health Perspectives</i> , 2021, 129, 17003.	6.0	15
10	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. <i>Nature Communications</i> , 2021, 12, 293.	12.8	54
11	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 181-199.	2.8	19
12	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. <i>Nature Communications</i> , 2021, 12, 1861.	12.8	68
13	Comorbidities in multiple myeloma and implications on survival: A population-based study. <i>European Journal of Haematology</i> , 2021, 106, 774-782.	2.2	18
14	Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. <i>European Journal of Haematology</i> , 2021, 107, 137-144.	2.2	2
15	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. <i>Pathology</i> , 2021, 53, 385-399.	0.6	12
16	Familial patterns of hematologic precursors. <i>Blood</i> , 2021, 137, 1992-1993.	1.4	0
17	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. <i>Blood Cancer Journal</i> , 2021, 11, 94.	6.2	52
18	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. <i>Clinica Chimica Acta</i> , 2021, 516, 136-141.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	4.6	50
20	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	7.1	63
21	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. <i>JAMA Oncology</i> , 2021, 7, 1678.	7.1	12
22	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2021, 106, 380-388.	2.2	6
23	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 191.	6.2	7
24	Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 662-672.	2.5	11
25	Diagnosed with myeloma before age 40. <i>Blood</i> , 2021, 138, 2601-2602.	1.4	1
26	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34++Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 58-65.	2.0	8
27	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e30-e37.	0.4	75
28	Future prospects of chimeric antigen receptor Tâ€¢cell therapy for multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e72.	0.9	0
29	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma. <i>JAMA Oncology</i> , 2020, 6, 425.	7.1	41
30	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2020, 396, 186-197.	13.7	299
31	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	12.8	41
32	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	5.0	46
33	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz104.	2.9	10
34	Mass Spectrometryâ€¢Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 901-911.	2.8	22
35	Comparison of MALDIâ€¢TOF mass spectrometry analysis of peripheral blood and bone marrowâ€¢based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 904-907.	2.5	40
36	Fractures and survival in multiple myeloma: results from a population-based study. <i>Haematologica</i> , 2020, 105, 1067-1073.	3.5	29

#	ARTICLE	IF	CITATIONS
37	Timing the initiation of multiple myeloma. Nature Communications, 2020, 11, 1917.	12.8	99
38	Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 269-278.	2.3	4
39	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1394-1401.	2.0	8
40	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncology, 2019, 5, 1293.	7.1	57
41	Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia, 2019, 33, 2127-2143.	7.2	36
42	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports, 2019, 9, 14884.	3.3	3
43	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. American Journal of Hematology, 2019, 94, 1364-1373.	4.1	22
44	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLoS ONE, 2019, 14, e0211600.	2.5	24
45	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. British Journal of Haematology, 2019, 186, 37-44.	2.5	0
46	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer Journal, 2019, 9, 15.	6.2	30
47	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology, 2019, 291, 5-13.	7.3	209
48	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e213-e220.	0.4	9
49	Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Advances, 2019, 3, 2040-2044.	5.2	50
50	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal, 2019, 9, 101.	6.2	40
51	Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018. Advances in Cell and Gene Therapy, 2019, 2, e26.	0.9	19
52	Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. Clinical Advances in Hematology and Oncology, 2019, 17, 559-568.	0.3	8
53	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. European Journal of Haematology, 2018, 101, 237-244.	2.2	107
54	Epidemiology and Pathophysiology of Multiple Myeloma. Hematologic Malignancies, 2018, , 1-15.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. <i>Modern Pathology</i> , 2018, 31, 881-889.	5.5	8
56	Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1445-1449.	2.4	12
57	Monoclonal Gammopathy of Undetermined Significance. , 2018, , 525-530.		0
58	MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. <i>Seminars in Hematology</i> , 2018, 55, 44-50.	3.4	31
59	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , 2018, 103, e412-e415.	3.5	87
60	MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool. <i>Seminars in Hematology</i> , 2018, 55, 1-3.	3.4	25
61	A Benefitâ€Risk Analysis Approach to Capture Regulatory Decisionâ€Making: Multiple Myeloma. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 67-76.	4.7	14
62	Host-related immunodeficiency in the development of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1127-1132.	1.3	16
63	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. <i>JAMA Oncology</i> , 2018, 4, 1781.	7.1	33
64	Dietary intake is associated with risk of multiple myeloma and its precursor disease. <i>PLoS ONE</i> , 2018, 13, e0206047.	2.5	19
65	Biological determinants of health disparities in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 85.	6.2	29
66	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>Annals of Hematology</i> , 2017, 96, 261-269.	1.8	20
67	A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. <i>Haematologica</i> , 2017, 102, 910-921.	3.5	187
68	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017, 23, 3980-3993.	7.0	71
69	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 217-221.	2.3	3
70	Proteomic profiling in plasma cell disorders: a feasibility study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1757-1759.	1.3	7
71	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. <i>Obesity</i> , 2017, 25, 1317-1320.	3.0	17
72	Racial/ethnic disparities: need more work!. <i>Blood</i> , 2017, 130, 1685-1686.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Epidemiology of Waldenström Macroglobulinemia. , 2017, , 97-109.		1
74	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma, 2017, 58, 639-645.	1.3	11
75	Serum protein markers of clonal heterogeneity in myeloma. Lancet Haematology,the, 2017, 4, e565-e566.	4.6	0
76	Shall we treat smoldering multiple myeloma in the near future?. Hematology American Society of Hematology Education Program, 2017, 2017, 194-204.	2.5	25
77	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Advances, 2017, 1, 728-732.	5.2	84
78	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	5.2	37
79	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Advances, 2017, 1, 2186-2192.	5.2	47
80	Title is missing!. , 2017, , .		0
81	Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. Seminars in Oncology, 2016, 43, 703-706.	2.2	1
82	Myeloma imaging: time to move on!. Leukemia and Lymphoma, 2016, 57, 1499-1500.	1.3	3
83	Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 187-193.	1.7	5
84	MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treatment and Research, 2016, 169, 3-12.	0.5	39
85	Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. American Journal of Hematology, 2016, 91, E502-E503.	4.1	18
86	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
87	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Seminars in Oncology, 2016, 43, 682-689.	2.2	53
88	New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5428-5433.	7.0	98
89	Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma. Current Radiology Reports, 2016, 4, 1.	1.4	0
90	Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leukemia and Lymphoma, 2016, 57, 1114-1121.	1.3	23

#	ARTICLE	IF	CITATIONS
91	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
92	No CLL transmission through blood transfusion. <i>Blood</i> , 2015, 126, 1978-1979.	1.4	3
93	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. <i>Haematologica</i> , 2015, 100, 1340-1349.	3.5	43
94	Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. <i>Pharmacotherapy</i> , 2015, 35, 1173-1188.	2.6	51
95	Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e493-e503.	3.8	11
96	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 746.	7.1	266
97	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , 2015, 100, 107-113.	3.5	356
98	Minimal residual disease in multiple myeloma: bringing the bench to the bedside. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 286-295.	27.6	97
99	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2288-2295.	1.6	106
100	Smoldering multiple myeloma. <i>Blood</i> , 2015, 125, 3069-3075.	1.4	211
101	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 669-678.	2.8	36
102	Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance. <i>JAMA Oncology</i> , 2015, 1, 1061.	7.1	56
103	Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. <i>ELife</i> , 2015, 4, e08153.	6.0	84
104	Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDAâ€NCI roundtable symposium. <i>American Journal of Hematology</i> , 2014, 89, 1159-1160.	4.1	52
105	The Road to Treating Smoldering Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S59-S64.	0.4	2
106	Common communityâ€acquired infections and subsequent risk of multiple myeloma: A populationâ€based study. <i>International Journal of Cancer</i> , 2014, 134, 1734-1740.	5.1	15
107	Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. <i>Haematologica</i> , 2014, 99, 1769-1771.	3.5	3
108	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 87-97.	2.1	32



#	ARTICLE	IF	CITATIONS
109	Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 332-342.	2.5	48
110	Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. <i>European Journal of Radiology</i> , 2014, 83, 970-974.	2.6	11
111	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
112	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. <i>Blood</i> , 2014, 123, 338-345.	1.4	105
113	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	10.7	3,343
114	Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. <i>Haematologica</i> , 2014, 99, 392-398.	3.5	249
115	Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 187-190.	0.4	8
116	Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. <i>Blood</i> , 2013, 122, 1088-1089.	1.4	85
117	Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. <i>American Journal of Hematology</i> , 2013, 88, 60-65.	4.1	66
118	Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. <i>American Journal of Hematology</i> , 2013, 88, 89-92.	4.1	7
119	Etiology of Waldenström Macroglobulinemia: Genetic Factors and Immune-related Conditions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 194-197.	0.4	10
120	Evolving therapeutic paradigms for multiple myeloma: back to the future. <i>Leukemia and Lymphoma</i> , 2013, 54, 451-463.	1.3	15
121	Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging of early myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1355-1363.	1.3	90
122	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 478-487.	2.5	69
123	Plasma Cell Neoplasms in US Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1523-1532.	4.7	34
124	Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. <i>Leukemia and Lymphoma</i> , 2013, 54, 2215-2218.	1.3	86
125	Pursuing the curative blueprint for early myeloma. <i>Blood</i> , 2013, 122, 486-490.	1.4	17
126	MGUS prevalence in an ethnically Chinese population in Hong Kong. <i>Blood</i> , 2013, 121, 2363-2364.	1.4	23



#	ARTICLE	IF	CITATIONS
127	Thromboprophylaxis in multiple myeloma: is the evidence there?. Expert Review of Anticancer Therapy, 2012, 12, 291-294.	2.4	4
128	Thrombosis is associated with inferior survival in multiple myeloma. Haematologica, 2012, 97, 1603-1607.	3.5	66
129	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica, 2012, 97, 854-858.	3.5	110
130	Second malignancies after multiple myeloma: from 1960s to 2010s. Blood, 2012, 119, 2731-2737.	1.4	108
131	Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood, 2012, 120, 4929-4937.	1.4	41
132	A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood, 2012, 120, 4418-4420.	1.4	58
133	Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. British Journal of Haematology, 2012, 157, 125-127.	2.5	8
134	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood, 2011, 117, 5573-5581.	1.4	161
135	What Causes Waldenström's Macroglobulinemia: Genetic or Immune-Related Factors, or a Combination?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 85-87.	0.4	10
136	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Review of Molecular Diagnostics, 2011, 11, 593-603.	3.1	35
137	Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. Seminars in Hematology, 2011, 48, 46-54.	3.4	13
138	Molecular Imaging in Myeloma Precursor Disease. Seminars in Hematology, 2011, 48, 22-31.	3.4	23
139	Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities. Seminars in Hematology, 2011, 48, 1-3.	3.4	8
140	Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. Seminars in Hematology, 2011, 48, 66-72.	3.4	7
141	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood, 2011, 118, 6284-6291.	1.4	74
142	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood, 2011, 118, 4086-4092.	1.4	173
143	Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. American Journal of Hematology, 2011, 86, 475-478.	4.1	38
144	High prevalence of polyclonal hypergammaglobulinemia in adult males in Ghana, Africa. American Journal of Hematology, 2011, 86, 554-558.	4.1	10

#	ARTICLE	IF	CITATIONS
145	Current and future imaging modalities for multiple myeloma and its precursor states. <i>Leukemia and Lymphoma</i> , 2011, 52, 1630-1640.	1.3	27
146	Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. <i>Journal of Clinical Oncology</i> , 2011, 29, 2514-2520.	1.6	183
147	From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention. <i>Clinical Cancer Research</i> , 2011, 17, 1243-1252.	7.0	68
148	Racial Differences in Chronic Immune Stimulatory Conditions and Risk of Non-Hodgkin's Lymphoma in Veterans From the United States. <i>Journal of Clinical Oncology</i> , 2011, 29, 378-385.	1.6	45
149	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. <i>Blood</i> , 2010, 116, 1056-1059.	1.4	137
150	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. <i>Blood</i> , 2010, 116, 2651-2655.	1.4	89
151	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. <i>Blood</i> , 2010, 116, 5501-5506.	1.4	308
152	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	1.4	204
153	Evolution of a precursor. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 1-3.	1.5	1
154	Different biology and clinical outcome according to the absolute numbers of clonal Bâ€œcells in monoclonal Bâ€œcell lymphocytosis (MBL). <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S19-23.	1.5	86
155	Prevalence of monoclonal Bâ€œcell lymphocytosis: A systematic review. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S10-8.	1.5	40
156	Prevalence, clinical aspects, and natural history of IgM MGUS. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S91-7.	1.5	20
157	Monoclonal B cell lymphocytosis: Clinical and population perspectives. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S115-9.	1.5	7
158	A Case Study Progression to Multiple Myeloma. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 419-422.	0.6	0
159	Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1229-1237.	2.5	41
160	Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 830-834.	1.6	165
161	Multiple Myeloma Precursor Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2397.	7.4	48
162	Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom Macroglobulinemia. <i>Journal of the National Cancer Institute</i> , 2010, 102, 557-567.	6.3	83

#	ARTICLE	IF	CITATIONS
163	Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma. Journal of Clinical Oncology, 2010, 28, 773-779.	1.6	101
164	Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. Hematology American Society of Hematology Education Program, 2010, 2010, 295-302.	2.5	25
165	Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Review of Molecular Diagnostics, 2010, 10, 465-480.	3.1	52
166	Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the Clinic. Mayo Clinic Proceedings, 2010, 85, 225-230.	3.0	113
167	Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 248-257.	0.4	18
168	Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leukemia and Lymphoma, 2010, 51, 2159-2170.	1.3	25
169	Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas. European Journal of Clinical & Medical Oncology, 2010, 2, 119-126.	0.0	12
170	Cancer Incidence among Pesticide Applicators Exposed to Permethrin in the Agricultural Health Study. Environmental Health Perspectives, 2009, 117, 581-586.	6.0	101
171	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 2009, 113, 5412-5417.	1.4	904
172	Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology, 2009, 49, 116-123.	7.3	253
173	Autoimmunity and lymphomagenesis. International Journal of Cancer, 2009, 124, 1497-1502.	5.1	89
174	Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. International Journal of Cancer, 2009, 125, 398-405.	5.1	221
175	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. International Journal of Cancer, 2009, 125, 2147-2150.	5.1	63
176	Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. British Journal of Haematology, 2009, 144, 86-94.	2.5	220
177	Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. British Journal of Haematology, 2009, 147, 444-449.	2.5	55
178	Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 19-22.	1.4	25
179	Genetics- and Immune-Related Factors in the Pathogenesis of Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 23-26.	1.4	16
180	B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2009, 360, 659-667.	27.0	322

#	ARTICLE	IF	CITATIONS
181	Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates. Cancer Journal (Sudbury, Mass ), 2009, 15, 473-478.	2.0	3
182	Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood, 2009, 113, 6386-6391.	1.4	137
183	Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood, 2009, 114, 4928-4932.	1.4	70
184	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood, 2009, 114, 791-795.	1.4	133
185	Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions. Blood, 2009, 114, 2356-2357.	1.4	3
186	Risk of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia Among 120 908 US Veterans With Hepatitis C Virus Infection. Archives of Internal Medicine, 2009, 169, 357.	3.8	67
187	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica, 2009, 94, 1714-1720.	3.5	95
188	Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica, 2009, 94, 1581-1589.	3.5	30
189	Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica, 2009, 94, 1259-1265.	3.5	72
190	Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica, 2009, 94, 647-653.	3.5	113
191	Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis and Rheumatism, 2008, 58, 657-666.	6.7	106
192	Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood, 2008, 111, 3388-3394.	1.4	195
193	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance—reply—I. Mayo Clinic Proceedings, 2008, 83, 602-603.	3.0	0
194	Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3069-3075.	2.5	100
195	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance—reply—I. Mayo Clinic Proceedings, 2008, 83, 602-603.	3.0	1
196	Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. Blood, 2008, 112, 3052-3056.	1.4	143
197	Chronic Immune Stimulation and Subsequent Waldenström Macroglobulinemia. Archives of Internal Medicine, 2008, 168, 1903.	3.8	48
198	Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. Journal of Clinical Oncology, 2007, 25, 1993-1999.	1.6	275

#	ARTICLE	IF	CITATIONS
199	Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus. JAMA - Journal of the American Medical Association, 2007, 297, 2010.	7.4	294
200	Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease. Archives of Internal Medicine, 2007, 167, 1189.	3.8	38
201	Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood, 2007, 109, 2198-2201.	1.4	89
202	Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood, 2007, 110, 4599-4605.	1.4	35
203	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. Mayo Clinic Proceedings, 2007, 82, 1468-1473.	3.0	142
204	Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. International Journal of Cancer, 2007, 121, 2260-2266.	5.1	104
205	Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. British Journal of Haematology, 2007, 139, 672-686.	2.5	80
206	Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. British Journal of Haematology, 2007, 139, 809-819.	2.5	185
207	Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 791-798.	2.5	52
208	Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. British Journal of Haematology, 2007, 139, 717-723.	2.5	24
209	Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Case-Control Study in Scandinavia. Journal of the National Cancer Institute, 2006, 98, 1321-1330.	6.3	179
210	Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood, 2006, 107, 904-906.	1.4	280
211	Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood, 2006, 108, 292-296.	1.4	63
212	Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and white veterans. Blood, 2006, 108, 1111-1112.	1.4	26
213	Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. International Journal of Cancer, 2006, 118, 3095-3098.	5.1	125
214	Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2342-2347.	2.5	55
215	Response to Splenectomy Is Durable after a Certain Point in Time in Adult ITP Patients.. Blood, 2005, 106, 3976-3976.	1.4	0
216	Antibody Response to Pneumococcal Polysaccharide Vaccination Predicts Pneumococcal Disease in Splenectomized Patients with Hematological Diseases.. Blood, 2004, 104, 1335-1335.	1.4	9

#	ARTICLE	IF	CITATIONS
217	Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica, 2003, 88, 438-44.	3.5	78
218	Parental longevity and survival in elderly patients with Hodgkin's lymphoma. Haematologica, 2002, 87, 596-601.	3.5	1